scispace - formally typeset
W

Weidong Han

Researcher at Sir Run Run Shaw Hospital

Publications -  123
Citations -  12142

Weidong Han is an academic researcher from Sir Run Run Shaw Hospital. The author has contributed to research in topics: Autophagy & Cancer. The author has an hindex of 34, co-authored 103 publications receiving 9472 citations. Previous affiliations of Weidong Han include Zhejiang University.

Papers
More filters
Journal ArticleDOI

A microRNA disease signature associated with lymph node metastasis of lung adenocarcinoma

TL;DR: The miRNA disease signature can be used as a noninvasive method to predict LNM in patients with lung adenocarcinoma objectively and the signature achieved high accuracy for prediction.
Journal ArticleDOI

The roles of transmembrane family proteins in the regulation of store-operated Ca2+ entry

TL;DR: The TMEM proteins that are involved in SOCE are summarized to better describe a picture of the interaction between STIM and ORAI proteins during SOCE and its downstream signaling pathways, as well as to provide an idea for the study of the TMEM family proteins.
Journal ArticleDOI

Lymph node involvement in pancreatic neuroendocrine tumors: significance as a predictor of survival

TL;DR: A lymph node involvement model was developed based on the predictors including age, marital status, primary site, T status, and tumor grade and showed great performance in C-index and area under receiver operating characteristic curve.
Journal ArticleDOI

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy

TL;DR: In this paper , the authors investigated the synergistic effects of radiofrequency ablation (RFA) and neoantigen vaccination in cancer patients and tumor-bearing mice and found that the combination of PD-1 blockage with RFA and neo-antigen vaccines further enhanced the antitumor response in mice.
Patent

Chimeric antigen receptor, gene of chimeric antigen receptor, recombinant expression vector of chimeric antigen receptor, CD22-CD19 double-targeting T cell and application of cell

TL;DR: In this paper, the chimeric antigen receptor was used to detect tumor cells co-expressed by two target spots of the CD19 antigen and the CD22antigen, compared with the single target spot CAR T, the double target spots CAR T have stronger anti-tumor activity, so that the immune escape of the tumor cells expressed by the low-abundance antigen is avoided, and therefore the recurrence risk is reduced.